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Abstract: Immunotherapy is the only treatment for allergy that has the potential to alter the 
natural course of the disease. Sublingual immunotherapy (SLIT) for grass pollen-induced 
rhino-conjunctivitis has been developed to make immunotherapy available to a broader group 
of allergic patients. In the largest clinical programme ever conducted with allergen-speciﬁ  c 
immunotherapy, over 1,700 adults and 260 children have been exposed to Grazax®. Grazax 
is formulated as an oral lyophilisate (tablet) for sublingual administration, containing 75,000 
SQ-T standardized allergen extract of grass pollen from Phleum pratense. Grazax is indicated 
for treatment of grass pollen-induced rhinitis and conjunctivitis in adult patients with clinically 
relevant symptoms and diagnosed with a positive skin prick test and/or speciﬁ  c IgE test to grass 
pollen. In phase I trials doses from 2,500 to 1,000,000 SQ-T were tested. All doses were well 
tolerated and 75,000 SQ-T, with approximately 15 μg major allergen protein, was chosen as 
the optimal dose. Three phase III trials are ongoing, one being a long-term trial. Results from 
GT-08 trial ﬁ  rst and second treatment years showed a reduction of 30% and 36%, respectively, 
in daily rhino-conjunctivitis symptom scores and a reduction of 38% and 46% of daily rhino-
conjunctivitis medication scores compared with placebo over the entire grass pollen season. 
Subjects treated with Grazax also had an increased number of well days and improved quality 
of life, and more subjects experienced excellent rhino-conjunctivitis control. The most common 
adverse events related to Grazax are local reactions, such as pruritus, edema mouth, ear pruritus, 
throat irritation, and sneezing. We conclude that Grazax is efﬁ  cacious and safe for treatment of 
rhino-conjunctivitis due to grass pollen allergy.
Keywords: sublingual immonotherapy, grass pollen allergy, rhinoconjunctivitis, 
immunotherapy, tablet
Introduction
Overall, it is estimated that one quarter of the European population suffers from 
respiratory allergies such as allergic rhinitis, and the prevalence is increasing, although 
it varies among countries (Linneberg et al 2000; Dahl et al 2004). Grass pollen is the 
most common cause of respiratory allergies, and is associated with more than 50% of 
allergic rhinitis cases (Bauchau and Durham 2004). Allergic rhinitis can leave a signiﬁ  -
cant burden of residual symptoms even among those receiving optimal symptomatic 
treatment (White et al 1998). Only allergen-speciﬁ  c immunotherapy (SIT) targets 
the underlying allergic disease, having the potential to produce long-term remission 
and to prevent the development of new sensitizations and asthma. SIT increases the 
tolerability to a speciﬁ  c allergen, thereby reducing the allergic symptoms and the 
consumption of symptomatic treatment.
Grazax® (ALK-Abello A/S, Hoersholm, Denmark) is the ﬁ  rst registered and 
marketed allergy tablet (oral lyophilisate) to treat the underlying cause of grass 
pollen-induced rhinoconjunctivitis in adult subjects. In order to ensure treatment of 
subjects with the correct indication, Grazax should be prescribed only by doctors with 
special knowledge and experience in treating allergic diseases. Grazax is a home-based Therapeutics and Clinical Risk Management 2008:4(6) 1256
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treatment and requires fewer visits to the doctor compared 
with traditional subcutaneous SIT. Visits are greatly reduced 
from 39 with subcutaneous SIT to about 6 visits with Grazax, 
contributing to a more cost-effective treatment compared 
with subcutaneous treatment under the conviction that the 
treatment is as effective.
Doses and substance
The recommended daily dose for adults is one tablet/
oral lyophilisate (75,000 SQ-T/2,800 BAU), containing 
approximately 15 μg major allergen Phleum pratense 
(Calderon et al 2007). Subjects should start treatment as a 
minimum 2 months prior to the grass pollen season without 
any up-dosing period (Calderon et al 2005). Grazax contains 
the same active pharmaceutical ingredient (API) as Alutard 
SQ® grass pollen, which has been used for more than 20 years 
as a subcutaneous SIT. The API is a standardized allergen 
extract from Phleum pratense grass pollen. It has been shown 
to have extensive cross-reactivity of allergenic components of 
grass pollens from different species (Andersson and Lidholm 
2003; Weber 2005).
Pharmacokinetics
As the active molecules of the allergens in Grazax are 
polypeptides and proteins, it is expected that these are 
hydrolyzed to amino acids and small polypeptides in the 
lumen of the gastrointestinal tract and in the local tissues. 
There is no evidence to suggest that the allergens present in 
Grazax are absorbed into the vascular system to any signiﬁ  cant 
extent (Senel et al 2001; Bagnasco et al 2003, 2005; 
Moingeon et al 2006). Consequently, no pharmacokinetics 
trials have been conducted.
Mechanism of action – 
pharmacodynamics in humans
The mechanism of SIT is very complex and the exact 
mechanism of action is still not fully understood. How-
ever, it is widely acknowledged that subcutaneous and 
sublingual SIT acts as a modiﬁ  er of the immune system. 
The mechanism is a combination of altered regulation of 
IgE syntheses and induction of IgE-blocking antibodies, 
with the capacity to competitively inhibit the interaction 
between allergen and IgE. Further effects include a shift 
from Th2 to regulatory T-cells and inhibition of facilitating 
antigen presentation of the speciﬁ  c T-cells. For Grazax it 
is documented that the amount of antibodies in serum is 
dependent on doses, and Grazax and Alutard SQ Phleum 
pratense give a clear and qualitatively similar antibody 
response (Malling et al 2006).
Clinical trials
The clinical development program for Grazax was initiated 
to investigate the optimal dosing regimen as well as the 
tolerability, safety, and efﬁ  cacy proﬁ  le of Grazax.
Five phase I trials (GT-01, GT-03, GT-04, GT-09 and 
GT-11) assessed the tolerability. Doses from 2,500 to 
1,000,000 SQ-T were tested in subjects with grass pol-
len allergy without any up-dosing period for any of the 
doses. The highest dose tested was 13 times higher than the 
approved dose (75,000 SQ-T). Even the high doses of Grazax 
were well tolerated, primarily with local adverse events, 
and no serious or systemic adverse events were reported 
(Kleine-Tebbe et al 2006). Furthermore, clinical safety and 
efﬁ  cacy were investigated in a phase II/III trial (GT-02), 
one phase II trial (GT-07) and one phase III efﬁ  cacy trial 
(GT-08). Long-term efﬁ  cacy and safety were investigated in 
an extension of the GT-08 trial, and interim results after 1 and 
2 years have been published (Dahl et al 2006a, 2008). The 
effect of a compliance device on treatment compliance was 
investigated in a phase IIIb trial (GT-10 trial). Three phase 
III trials are ongoing, though the trial periods for GT-12 and 
GT-14 are completed.
The number of subjects exposed to Grazax in the 
completed clinical trials is 1,619; in addition 860 adults 
are exposed in the on-going GT-08 extension and GT-14 
study. A number of subjects are also exposed in relation to 
ongoing phase IV activities. The patient exposure on the 
market is, as of December 2007, 6,936 treatment years. 
Table 1 shows an overview of the completed and ongoing 
trials on Grazax.
Based on results from the ﬁ  rst year of GT-08, Grazax 
was approved in 27 European countries for treatment of 
grass pollen-induced rhinitis and conjunctivitis in adults with 
clinically relevant symptoms and diagnosed with a positive 
skin prick test and/or speciﬁ  c IgE test to grass pollen.
In GT-08, trial treatment was initiated at least 16 weeks 
before the anticipated start of the grass pollen season, 
and the efﬁ  cacy was measured according to the newest 
recommendation from the World Allergy Organisation 
(Canonica et al 2007). Six allergic symptoms were rated 
daily (runny nose, blocked nose, sneezing, itchy nose, gritty 
feeling/red/itchy eyes, and watery eyes). Subjects treated 
with Grazax had a numerically lower symptom score than 
the placebo group. This was evident in both nose and eye 
symptoms during the entire grass pollen season. During Therapeutics and Clinical Risk Management 2008:4(6) 1257
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Figure 1 Symptom score from the ﬁ  rst and second treatment year.
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Figure 2 Medication score from the ﬁ  rst and second treatment year.
the ﬁ  rst and second treatment years Grazax reduced mean 
daily rhino-conjunctivitis symptom score by 30% and 36%, 
respectively (Figure 1), and mean daily rhino-conjunctivitis 
medication score by 38% and 46%, respectively, compared 
with placebo over the entire grass pollen season (Figure 2). 
The differences in symptom and medication score differed 
signiﬁ  cantly (p   0.0001) from the placebo group. These 
results conﬁ  rmed results obtained from earlier trials with 
Grazax (Durham et al 2006; Dahl et al 2006b), and are con-
sistent with the efﬁ  cacy results reported for subcutaneous 
SIT (Frew et al 2006).
Subjects in the Grazax group also reported an increased 
number of well days during the grass pollen season 
(days with few symptoms and no need for rescue medi-
cation), improved quality of life (assessed by Juniper’s 
Rhino-conjunctivitis Quality of Life Questionnaire) (Junier 
and Guyatt 1991), and more subjects experienced excellent 
rhino-conjunctivitis control compared with the placebo 
group (Durham et al 2007; Rak et al 2007). These results 
support the contention that reductions in rhino-conjunctivitis 
medication and symptoms score translate into important 
beneﬁ  ts for the subjects and therefore can be considered 
clinically relevant.
In addition, 82% and 69% of the subjects treated 
with Grazax felt much better or better compared with 
previous grass pollen season during the ﬁ  rst and second 
year. For comparison 54% of the subjects (ﬁ  rst grass pollen 
season) and 57% of subjects (second grass pollen season) 
in the placebo group felt much better or better compared 
with previous grass pollen season. The high placebo 
effect can partly be explained by the fact that the placebo 
group used more medication than the Grazax group (Dahl 
et al 2006a).
Safety
Even though the reported efﬁ  cacy of subcutaneous and 
sublingual immunotherapy is of similar magnitude, the 
treatment regimen and the safety proﬁ  les are completely 
different. The expected adverse events (AE) during 
subcutaneous immunotherapy are largely of two types, 
local reactions at the injections site and systemic reactions 
characterized by generalized signs and/or symptoms 
occurring distant from the injection site. Since the injection 
of allergens against which a subject has IgE antibodies may 
induce anaphylactic shock, it is recommended that all subjects 
are observed for 20 or 30 minutes after each injection and 
the treatment should be performed only by specialists 
(Bousquet et al 1998). In contrast Grazax treatment is 
primarily characterized by frequent but local reactions, 
located in the mouth and throat, which mostly were mild 
to moderate. In the majority of the subjects these reactions 
started early in therapy, lasted from minutes to hours after 
each intake of Grazax, and tended to subside spontaneously 
within 1 to 7 days. The most common reported AE were 
oral pruritus, edema mouth, ear pruritus, throat irritation, 
and sneezing. Less commonly reported AE were headache, Therapeutics and Clinical Risk Management 2008:4(6) 1258
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Table 1 Overview of clinical trials on Grazax®
Trial ID Phase Trial objective/design Doses tested SQ-T Subjects
Completed trials GT-01 (12) I Single and multiple dose safety 
trial conducted outside the 
grass pollen season.
2,500; 25,000; 75,000; 
125,000; 375,000; placebo
52 subjects with 
allergy to grass pollen
GT-02 (5; 16; 17) II/III Efﬁ  cacy and safety trial. Max 
duration of treatment: 8 weeks 
prior to and then during the 
grass pollen season 2003.
2,500; 25,000; 75,000; 
placebo
855 subjects with 
allergy to grass pollen
GT-03 (13) I 28 days multiple dose, 
dose-escalation safety trial 
conducted outside the grass 
pollen season.
25,000; 75,000; 150,000; 
300,000; 500,000; 750,000; 
1,000,000; placebo
84 subjects with 
allergy to grass pollen
GT-04 (18) I 28 days multiple dose, 
dose-escalation safety trial 
conducted outside the grass 
pollen season.
75,000; 150,000; 300,000; 
500,000; placebo
43 subjects with 
allergy to grass pollen 
and mild to moderate 
asthma
GT-07 (5; 19) II Efﬁ  cacy and safety trial. 
Duration of treatment: approx 
12 weeks prior to and then 
during the grass pollen season 
2004.
75,000 placebo 114 subjects with 
allergy to grass pollen 
and mild to moderate 
grass pollen induced 
asthma
GT-08 (1st year) (5; 14; 15) III Efﬁ  cacy and safety trial. 
Duration of treatment: approx 
6 months prior to and then 
during the grass pollen season 
2005.
75,000 placebo 634 adult subjects 
with seasonal grass 
pollen-induced 
rhinoconjunctivitis
GT-08 (extension- 
2nd year)
III Efﬁ  cacy and safety trial. 
Duration of treatment: approx 
6 months prior to and then 
during the grass pollen season 
2006.
75,000 placebo 351 adult subjects 
with seasonal grass 
pollen-induced 
rhinoconjunctivitis
GT-09 (20) I 28 days single dose safety trial 
conducted outside the grass 
pollen season to conﬁ  rm the 
safety of Grass allergen tablet 
in children aged 5–12 years.
75,000 placebo 30 children aged 
5–12 years with 
grass pollen-induced 
rhinoconjunctivitis 
(with/without 
asthma)
GT-10 IIIb Compliance and safety trial. 
Duration of treatment: 6–12 
weeks prior to and then 
during the grass pollen season 
2006. Primary objective: To 
evaluate if subject compliance 
of once daily dosing with 
grass allergen tablet can be 
increased by providing subjects 
with a compliance device.
75,000 placebo 460 adult subjects 
with grass 
pollen-induced allergic 
rhinoconjunctivitis
GT-11 (20) I 28 days single dose safety trial 
conducted outside the grass 
pollen season to conﬁ  rm the 
safety of grass allergen tablet 
in children aged 5–12 years.
75,000 placebo 30 children aged 
5–12 years with 
grass pollen-induced 
rhinoconjunctivitis 
(with/without 
asthma)
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Table 1 (Continued)
Trial ID Phase Trial objective/design Doses tested SQ-T Subjects
Ongoing trials GT-08 (extension) III Long-term efﬁ  cacy and safety 
trial including a total of 3 years 
of treatment (2005–2007) 
and 2 years of follow-up 
(2008–2009).
75,000 placebo 287 subjects with 
seasonal grass 
pollen-induced 
rhinoconjunctivitis 
(representative 
subset of the subjects 
included in the 
original trial)
GT-12 III Efﬁ  cacy and safety trial 
in children (5–16 years). 
Duration of treatment: at least 
16 weeks prior to and then 
during the grass pollen season 
2007.
75,000 placebo 253 children aged 
5–16 years with 
grass pollen-induced 
rhinoconjunctivitis 
(with/without asthma)
GT-14 III Efﬁ  cacy and safety trial in an 
adult US population. Duration 
of treatment: 8–16 weeks 
prior to and then during the 
grass pollen season 2007.
75,000 placebo 320 subjects with 
seasonal grass 
pollen-induced 
rhinoconjunctivitis 
(with/without asthma)
oral paraesthesia, eye pruritus, conjunctivitis, cough, asthma, 
pharyngitis, rhinorrhoea, nasal congestion, rhinitis throat 
tightness, pruritus, and fatigue. As a precautionary action 
the ﬁ  rst tablet is administered in the clinic under medical 
supervison.
Grazax is contraindicated in the case of hypersensitivity 
to any of the excipients in the oral lyophilisate (tablet); in 
the case of malignancy or systemic diseases affecting the 
immune system; in case of inﬂ  ammatory conditions in the 
oral cavity with severe symptoms such as oral lichen planus 
with ulcerations or severe oral mycosis; and in patients with 
uncontrolled or severe asthma (FEV1   70% of predicted 
value after adequate pharmacologic treatment).
Trials in the pediatric population have also been 
performed (Ibanez et al 2007). Grazax was well tolerated in 
children, and further clinical investigations of the efﬁ  cacy 
and safety in children have shown corresponding effects to 
the results from the trials in adults which led to the European 
marketing approval in 2006.
Grazax has been demonstrated to be efﬁ  cacious and well 
tolerated as home treatment and this treatment concept might 
allow immunotherapy treatment for a broader population 
including subjects not having easy access to specialists in 
immunotherapy and subjects who have been reluctant to 
undergo injection immunotherapy.
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